Navigation Links
Alimera Sciences Names European Management Team
Date:11/14/2012

St. Helens and Knowsley School of Nursing, Merseyside, a renal and urology specialist nursing degree from Oxford School of Nursing, Oxford, and a Bachelor of Arts in health studies from Oxford Brookes University.

About ILUVIEN®

ILUVIEN (190 micrograms fluocinolone acetonide intravitreal implant in applicator) is a sustained release intravitreal implant used to treat patients with chronic DME considered insufficiently responsive to available therapies. Each ILUVIEN implant provides a therapeutic effect of up to 36 months by delivering sustained sub-microgram levels of fluocinolone acetonide (FAc). ILUVIEN is injected in the back of the patient's eye to a position that takes advantage of the eye's natural fluid dynamics. The applicator employs a 25-gauge needle, which allows for a self-sealing wound. In Alimera's FAME Study, the most frequently reported adverse drug reactions included cataract operation, cataract and increased ocular pressure.

In July 2010, Alimera submitted a Marketing Authorization Application (MAA) to seven European countries via the Decentralized Procedure (DCP) with the Medicines and Healthcare products Regulatory Agency of the U.K. (MHRA) serving as the Reference Member State (RMS). The MAA included data from two Phase 3 pivotal clinical trials for ILUVIEN conducted by Alimera (collectively known as the FAME Study). The trials involved 956 patients in sites across the United States, Canada, Europe and India to assess the efficacy and safety of ILUVIEN for the treatment of DME. At the end of the DCP, a consensus was reached by the RMS and the other six countries that the MAA for ILUVIEN was approvable. To date, five of the seven countries, Austria, the United Kingdom, Portugal, France and Germany, have granted national licenses for ILUVIEN. ILUVIEN has not been approved by the United States Food and Drug Administration.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., based in Alpharetta, Geo
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alimera Sciences To Present At 2012 Stifel Nicolaus Healthcare Conference
2. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
3. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
4. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
8. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
9. Neurocrine Biosciences Reports First Quarter 2012 Results
10. Remedy Informatics Named "Cool Vendor" in Life Sciences by Leading Technology Analyst Firm
11. Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015   NineSigma the leading innovation partner ... in estimated overall revenue growth and anticipates the creation of ... Open Innovation Incentive (OII). In 2013, the ... grant of over $2 million to accelerate adoption of open ... Million and $1 Billion in revenues. To date over 45 ...
(Date:8/27/2015)... 27, 2015  Hill-Rom Holdings, Inc., (NYSE: HRC ... at the Morgan Stanley Global Healthcare Conference on September ... are invited to listen to the live discussion via ... directly at https://cc.talkpoint.com/morg007/091615a_ae/?entity=49_UCJPU8N . A recorded ... after the conclusion of the live event and accessible ...
(Date:8/27/2015)... TORONTO , Aug. 27, 2015  Generex Biotechnology ... issuance of a white paper on the status of ... The white paper was presented to the August 19, ... James H. Anderson, Jr. , MD, the Company,s ... online on the Generex website. The white ...
Breaking Medicine Technology:State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 2State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 3Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4
... Reportlinker.com announces that a new market research ... Global Kidney Stone Management ... http://www.reportlinker.com/p0611035/Global-Kidney-Stone-Management-Devices-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_D This report analyzes ... Devices in US$ Million by the following ...
... RMD ) announced today that it will be presenting ... Conference at the Grand Hyatt in New York City on September ... Grand Hyatt in New York City on September 20, 2011; ... in Phoenix, AZ on November 9, 2011; Piper Jaffray Healthcare ...
Cached Medicine Technology:Global Kidney Stone Management Devices Industry 2Global Kidney Stone Management Devices Industry 3Global Kidney Stone Management Devices Industry 4Global Kidney Stone Management Devices Industry 5Global Kidney Stone Management Devices Industry 6Global Kidney Stone Management Devices Industry 7Global Kidney Stone Management Devices Industry 8Global Kidney Stone Management Devices Industry 9Global Kidney Stone Management Devices Industry 10Global Kidney Stone Management Devices Industry 11ResMed Inc. to Present at Upcoming Conferences 2
(Date:8/27/2015)... ... August 27, 2015 , ... Thriveology Founders, Dr. Carly Letzt Carney and ... Amazing Aging Expo in Denver, Colorado on Saturday, August 29, 2015 at the Marriott ... media outlets as health authorities, and will present a two part seminar entitled, “How ...
(Date:8/27/2015)... ... August 27, 2015 , ... On May 30th, 2015, at the ... as sponsor of the “Music With A Mission” benefit concert. For the past two ... programs in the underfunded school districts of Mendon and neighboring town, Quincy, IL. Organized ...
(Date:8/27/2015)... , ... August 27, 2015 , ... The Naderi Center ... be offering Kybella, a cutting-edge, noninvasive procedure to improve submental fat. The first ... provides permanent results without surgery. Dr. Kulak is the only Board Certified surgeon ...
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... Healthpointe ... into its La Tijera Clinic in Los Angeles. Licensed to practice Chinese Needle Therapy ... emphasis on neuromuscular injuries and diseases. Dr. Priebe also practices in Healthpointe’s La Mirada ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... In addition ... Alvernia University now offers a third doctoral program at its main campus in Reading: ... a terminal degree program designed to prepare advanced practice nurses for the highest level ...
Breaking Medicine News(10 mins):Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2Health News:Best Drug Rehabilitation Interviews Madd Hoss Jackson at the 2015 "Music With A Mission" Benefit Concert 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2
... international team of pathologists studied an initial 4,000 prostate cancer ... into the natural progression of the disease and how it ... British Journal of Cancer , could be used to develop ... of prostate cancer. Globally, prostate cancer is ...
... people worldwide, researchers say , WEDNESDAY, Sept. 23 (HealthDay ... only one injection produced promising results in animals, U.S. ... to undergo six shots over 28 days -- five ... rabies immunoglobulin. , The new replication-deficient rabies virus vaccine ...
... ... Training from American TeleCare, Inc. to Integrate Telehealth into the Education and Clinical Practice ... ... (ATI), Inc. announced that the Allied Health Department, University of Hawaii-Maui Community College (UH-Maui ...
... BERLIN, Sept. 23 Bayer HealthCare Pharmaceuticals ... today announced the full results from their first collaborative ... Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic ... advanced breast cancer. The data were presented at ...
... ... has been officially recognized by the City of Chicago. In honor of this day, The ... local celebrations. , ... (PRWEB) September 23, 2009 -- Christopher Reeve Day (9/25) has been officially recognized by the ...
... ... MD and Cell Biologist Jose Minguell, PhD,s adult stem cell human clinical ... Stem Cell Summit in Baltimore, MD. All of the trial patients ... diabetic patients reported pain from diabetic neuropathy has ceased. TCA Cellular ...
Cached Medicine News:Health News:Study reveals 2/3 of prostate cancer patients do not need treatment 2Health News:One Shot May Someday Replace Six for Rabies 2Health News:University of Hawaii-Maui Community College Selects American TeleCare for Allied Health Department's Nursing Telehealth Project 2Health News:University of Hawaii-Maui Community College Selects American TeleCare for Allied Health Department's Nursing Telehealth Project 3Health News:Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study 2Health News:Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study 3Health News:Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study 4Health News:Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study 5Health News:Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study 6Health News:First-Ever Christopher Reeve Day (9/25/09) to be Celebrated with Memorable Chicago Events 2Health News:Louisiana's TCA Cellular Therapy's Findings Reported at World Stem Cell Summit -- Patients' Legs Saved from Amputation Using Adult Stem Cells 2Health News:Louisiana's TCA Cellular Therapy's Findings Reported at World Stem Cell Summit -- Patients' Legs Saved from Amputation Using Adult Stem Cells 3
... The Zeus Scientific, Inc. ENA Profile-6 ... for the detection of IgG antibodies to ... in human sera. When performed according to ... autoantibody profile may aid in the diagnosis ...
Inquire...
... K-ASSAY Microalbumin Urine Controls are ... use liquid requiring no reconstitution ... from human urine, fortified to ... and creatinine. Preservatives including sodium ...
The K-ASSAY ITA Lyophilized Multi-Control Set is intended to be used as a consistent test sample of known concentration for monitoring the performance of K-ASSAY immunoturbidimetric assays for the li...
Medicine Products: